In a recent systematic review investigating the safety and efficacy of immune checkpoint inhibitors (PD-1 and/or CTLA-4 inhibitors) in HBV-/HCV-infected cancer patients, the authors concluded that immune checkpoint inhibitors are considered safe and effective in advanced cancer patients with HBV/HCV infection. The gene discussed is PDCD1; the disease is cancer.